What changed, and when
Bottom line
This is the log of every dated change recorded here: 113 entries, 64 of them linking to the document behind the change. Sites in this category publish prices but not the day they moved, which is how a withdrawn figure stays in circulation for a year after it stopped being true. The corrections among them are the latest 40 of 272; every one is on the corrections page.
Ending soon
- Wegovy first-fill price ends 2026-12-31 — 83 days from now. Novo Nordisk publishes it at $199 a month for 0.25 mg and 0.5 mg.
- Trulicity Savings Card ends 2026-12-31 — 83 days from now. Eli Lilly publishes it at as little as $25 for a 1-, 2- or 3-month fill.
- Mounjaro Savings Card ends 2026-12-31 — 83 days from now. Eli Lilly publishes it at as little as $25 for a 1-, 2- or 3-month fill.
- Zepbound savings card ends 2026-12-31 — 83 days from now. Eli Lilly publishes it at as little as $25 for up to a 3-month prescription.
- Ozempic first-fill price ends 2026-12-31 — 83 days from now. Novo Nordisk publishes it at $199 a month for the first two fills at 0.25 mg or 0.5 mg.
- Medicare GLP-1 Bridge ends 2027-12-31 — 448 days from now. Centers for Medicare & Medicaid Services publishes it at $50 a month.
What has changed recently in GLP-1 prices and coverage?
The dated record on this site runs to 113 entries across five kinds of change: a verified price moving, a state changing what its Medicaid program covers, a published offer reaching its end date, a documented event on a seller's public record, and this site correcting itself — the latest 40 of its 272 corrections. The next dated event is Wegovy first-fill price, which ends 2026-12-31 — 83 days away, at $199 a month for 0.25 mg and 0.5 mg. 7 approved price changes have been recorded from the nightly checker; 13 of the corrections below name a price as well. The reason to keep this log at all is narrow and demonstrable: Lilly cut the Zepbound savings card's annual ceiling from $1,950 to $1,300 and its monthly cap from $150 to $100, and a year later the superseded figure was still being published by a site ranking fourth for the query — in its own FAQ, on a page whose program block carried the corrected number. Neither figure had a date against it. Everything below does.
December 2027
- Offer ends2027-12-31
Centers for Medicare & Medicaid Services publishes it at $50 a month, with this as the last day.
December 2026
- Offer ends2026-12-31
Novo Nordisk publishes it at $199 a month for 0.25 mg and 0.5 mg, with this as the last day.
- Offer ends2026-12-31
Eli Lilly publishes it at as little as $25 for a 1-, 2- or 3-month fill, with this as the last day.
- Offer ends2026-12-31
Eli Lilly publishes it at as little as $25 for a 1-, 2- or 3-month fill, with this as the last day.
- Offer ends2026-12-31
Eli Lilly publishes it at as little as $25 for up to a 3-month prescription, with this as the last day.
- Offer ends2026-12-31
Novo Nordisk publishes it at $199 a month for the first two fills at 0.25 mg or 0.5 mg, with this as the last day.
October 2026
- State coverage2026-10-01
Rhode Island changed what its Medicaid program covers
GLP-1s prescribed only for weight loss (Foundayo, Saxenda, Wegovy and Zepbound) no longer covered, under the state's fiscal 2027 budget
September 2026
- We were wrong2026-09-14
The membership-fee answer on the PlushCare page said the price here adds the fee and the medication.
Now: The fee alone is not what a month costs, and no monthly total for PlushCare is recorded here. The PlushCare card holds no monthly total, so there was no such price; the sentence had been written for cards that hold both figures.
- We were wrong2026-09-14
Now: The fee alone is not what a month costs, and no monthly total for WeightWatchers Clinic is recorded here. The WeightWatchers Clinic card holds no monthly total, so there was no such price; the sentence had been written for cards that hold both figures.
- We were wrong2026-09-14
Now: The fee alone is not what a month costs, and no monthly total for Hims & Hers is recorded here. The Hims & Hers card holds no monthly total, so there was no such price; the sentence had been written for cards that hold both figures.
- We were wrong2026-09-14
The membership-fee answer on the Ro Body page said the price here adds the fee and the medication.
Now: The fee alone is not what a month costs, and no monthly total for Ro Body is recorded here. The Ro Body card holds no monthly total, so there was no such price; the sentence had been written for cards that hold both figures.
- We were wrong2026-09-14
Whether Sam's Club's pharmacy needs a membership
Was: Requires a paid Sam's Club membership. Now: No membership is needed to buy prescription medications. The card said a paid Sam's Club membership was required. Sam's Club's help center says you do not have to be a member to buy prescription medications there.
- We were wrong2026-09-14
Whether Sam's Club sells a GLP-1
Was: The Member Health program page stopped resolving; no price is left to verify. Now: Sam's Club Pharmacy's own page prices Zepbound KwikPens at $299 to $699 a month by dose. The card said the Sam's Club help-center page it was built on answered only an error, so no price was shown. The page answers again, and prices Zepbound KwikPens through Sam's Club Pharmacy at $299 to $699 a month by dose with the manufacturer's coupon.
- We were wrong2026-09-14
Whether MEDVi names its pharmacies
Was: No page of its could be read, so whether it names a compounding pharmacy was unknown. Now: Names Triad Rx, RedRock Pharmacy and Beaker Pharmacy & Compounding as its partner pharmacies. No page of MEDVi's could be read when this was last checked, on 10 September 2026. Its site, now at medvi.org, lists three partner pharmacies with their addresses in its footer.
- We were wrong2026-09-14
Was: No longer a telehealth site: medvi.com serves a parked-domain stub. Now: Trades from medvi.org: compounded semaglutide at $149 for the first month, refills at $299. The card said MEDVi was no longer a telehealth site because medvi.com served a parked-domain stub. MEDVi trades from medvi.org, whose program page prices compounded semaglutide at $149 for the first month and $299 a refill.
- Price2026-09-13
Compounded tirzepatide re-checked
From Noom Med, Found and Eden
- Price2026-09-13
Compounded semaglutide re-checked
From Strut Health, Zealthy, Shed, Lemonaid Health, Eden and Noom Med
- Price2026-09-13
Compounded tirzepatide re-checked
From Eden, Noom Med and Found
- Price2026-09-13
Compounded semaglutide re-checked
From Strut Health, Zealthy, Lemonaid Health, Eden and Noom Med
- Price2026-09-13
Compounded semaglutide re-checked
From Strut Health, Medvi, Zealthy, Shed, Lemonaid Health, Eden and Noom Med
- Price2026-09-13
Compounded tirzepatide re-checked
From Noom Med, Found and Eden
- Price2026-09-13
Compounded semaglutide re-checked
From Strut Health, Medvi, Zealthy, Shed, Lemonaid Health, Eden and Noom Med
- Price2026-09-13
Compounded tirzepatide re-checked
From Noom Med, Found and Eden
- Price2026-09-13
Compounded semaglutide re-checked
From Strut Health, Medvi, Zealthy, Shed, Lemonaid Health, Eden and Noom Med
- Price2026-09-13
Compounded tirzepatide re-checked
From Noom Med, Found and Eden
- Price2026-09-13
Compounded semaglutide re-checked
From Strut Health, Medvi, Zealthy, Shed, Lemonaid Health, Eden and Noom Med
- Price2026-09-13
Compounded tirzepatide re-checked
From Noom Med, Found and Eden
- Price2026-09-13
Compounded semaglutide re-checked
From Strut Health, Medvi, Zealthy, Shed, Lemonaid Health, Eden and Noom Med
- Price2026-09-13
Compounded tirzepatide re-checked
From Noom Med, Found and Eden
- Price2026-09-13
Compounded semaglutide re-checked
From Strut Health, Medvi, Zealthy, Shed, Lemonaid Health, Eden and Noom Med
- Price2026-09-13
Compounded tirzepatide re-checked
From Noom Med, Found and Eden
- Price2026-09-13
Compounded semaglutide re-checked
From Strut Health, Medvi, Zealthy, Shed, Lemonaid Health, Eden and Noom Med
- Price2026-09-13
Compounded tirzepatide re-checked
From Noom Med, Found and Eden
- Price2026-09-13
Compounded tirzepatide re-checked
From Noom Med, Found and Eden
- Price2026-09-13
Compounded semaglutide re-checked
From Strut Health, Medvi, Zealthy, Shed, Lemonaid Health, Eden and Noom Med
- We were wrong2026-09-13
Was: The domain is for sale and there is nothing left to read a price from. Now: Trades from tryshed.com: semaglutide from $159 or $249 a month, tirzepatide from $239 or $349, as its own pages print them. The card said Shed's site was gone because shed.com lands on a domain broker's for-sale page. Shed trades from tryshed.com, which prints compounded semaglutide from $159 a month and compounded tirzepatide from $239 in its banner, and $249 and $349 further down the same page.
- We were wrong2026-09-13
Strut Health's ongoing monthly price
Was: $99 a month on auto-refill. Now: $129 a month on auto-refill. The card's starting price moved to $129 a month on 13 September, when Strut's semaglutide page was re-read, but its ongoing price still held the $99 that came from a Google description and is no longer on the page. The page prints "$129/mo" on auto-refill, with no lower price for staying on.
- We were wrong2026-09-13
How Found bills its longer plans
Was: Billing every 28 days is thirteen charges a year, not twelve, and the cheaper terms are paid up front. Now: Found's pages disagree on how a longer plan is paid. Its plans page, joinfound.com/plans-and-pricing, says "Pricing based on 12-month plans paid up-front"; its offer terms, joinfound.com/terms/offer-terms-v3, price every plan length "per month, billed every 4 weeks (28-day cycle)", which is thirteen charges a year, not twelve. Before paying, ask Found whether a 12-month plan is charged all at once. The price note said Found's cheaper 3-, 6- and 12-month terms are paid up front. Read 13 September 2026, Found's own pages disagree: the plans page says "Pricing based on 12-month plans paid up-front", while the offer terms list every plan length at a price "per month, billed every 4 weeks (28-day cycle)". The note now gives both and tells the reader to ask Found before paying.
- We were wrong2026-09-13
Which price Found advertises, and what its 12-month plan commits you to
Was: The advertised $169 is a 12-month contract price. If you quit at month three you have still bought the year — read the cancellation clause before the first charge. Now: Found's headline, from $99 a month on a 12-month plan, is the price with insurance, and that track adds a video-visit copay of about $30. Paying cash, the 12-month price is $169 and month to month is $289, all-in per 28-day cycle. Found's plans page says 12-month pricing is "paid up-front" while its offer terms bill "every 4 weeks", and neither prints a rule for leaving early: ask whether the year is charged at once, and what quitting before month 12 costs, before you pick the long plan. The line called $169 Found's advertised price and said that quitting at month three still buys the whole year. On 13 September 2026 Found's compounded semaglutide page advertises from $99 a month on a 12-month plan, which is the price with insurance; $169 is the 12-month price paying cash, and $289 is month to month. Found's own pages disagree on how the year is paid: its plans page says "Pricing based on 12-month plans paid up-front", while its offer terms bill every plan length every 4 weeks, and neither states a charge for leaving early. The line now gives both and says to ask before choosing the long plan.
- We were wrong2026-09-13
Rhode Island's coverage ending on 1 October 2026
Was: Covered, with no end date recorded. Now: Covered until 30 September 2026; from 1 October Rhode Island Medicaid stops paying for Foundayo, Saxenda, Wegovy and Zepbound prescribed only for weight loss. An EOHHS memo of 5 August 2026 says that under the state's fiscal 2027 budget Rhode Island Medicaid will no longer cover certain GLP-1s prescribed solely for weight loss, beginning 1 October 2026, and names these four. The row said covered with no end recorded. Whether the non-GLP-1 weight-loss drugs stay covered is not yet confirmed: the preferred drug list could not be read on 13 September 2026.
- We were wrong2026-09-13
What Texas will approve Wegovy for
Was: The state's decision tree denies at step two when there is no cardiovascular diagnosis — so in Texas the question is not your BMI, it is whether your heart disease is documented. Now: Texas's current criteria, in force since 30 July 2026, approve Wegovy on two routes: documented cardiovascular disease with a diagnosis of obesity or overweight, for members 45 or older, or non-cirrhotic MASH with F2 to F3 liver fibrosis confirmed by biopsy or a non-invasive test within 180 days, for adults on the injection. Obesity alone is still denied, so in Texas the question is whether heart or liver disease is documented, not your BMI. The row cited Texas's October 2024 Wegovy criteria. The criteria in force for fee-for-service since 30 July 2026, Acentra's guide revised 8 May 2026, approve a second route beside cardiovascular disease: non-cirrhotic MASH with moderate to advanced fibrosis. In the current tree cardiovascular disease is step three, for members 45 or older, and MASH step four, so "denies at step two" no longer described it.
- We were wrong2026-09-13
Was: $315 to $415 a month through telehealth. Now: No price shown: no seller on this site offers branded Saxenda at a published cash price. The range came from Hone Health, counted here as a Saxenda seller. Hone's men's weight-loss page, read in a browser on 13 September 2026, sells "Compounded Liraglutide" at $160 a month plus membership, a compounded copy rather than Saxenda, so it no longer counts.
- We were wrong2026-09-13
GoodRx for Weight Loss's monthly price
Was: $188 to $388 a month. Now: From $188 a month: the $39 membership plus medication from $149. GoodRx's program page, read 13 September 2026, prints the $39 membership and medication "As low as $149". The $388 top added a $349 Wegovy pen price that page does not print; the GoodRx page that carried it could not be re-read.
- We were wrong2026-09-13
Whether Hone Health's liraglutide is branded
Was: Branded, FDA-approved medication with no compounding risk. Now: Compounded liraglutide, not the FDA-approved Saxenda. Hone's men's weight-loss page, read in a browser on 13 September 2026, lists "Compounded Liraglutide $160/mo + membership" and says "Compounded liraglutide is a daily injection". A compounded copy is not the FDA-approved product, and Hone had been counted as a seller of Saxenda.
- We were wrong2026-09-13
Was: $315 to $415 a month. Now: $315 a month: the $155 membership plus $160 for liraglutide. Hone's pages, read 13 September 2026, print the $155 membership and liraglutide at $160 a month. The $415 top of the range is printed on none of them.
- We were wrong2026-09-13
Was: A three-month minimum. Now: Month to month: "a subscription service that you can cancel anytime". Eden's weight-loss page, read 13 September 2026, calls its membership "a subscription service that you can cancel anytime" and bills it monthly: "$39 for the first month, auto-renews at $99/month thereafter". The three-month minimum came from a third-party report.
- We were wrong2026-09-13
Was: No price shown, because tryeden.com could not be read. Now: $198 a month for compounded semaglutide and $298 for tirzepatide: the $99 membership plus the medication. Eden's weight-loss page was read on 13 September 2026 through a rendering service. It prices the medication at $99 a month for compounded semaglutide and $199 for compounded tirzepatide, and requires a membership of $39 for the first month, then $99 a month.
- We were wrong2026-09-13
Was: $99 a month on auto-refill, $149 without it. Now: $129 a month on auto-refill for injectable semaglutide, $199 for the pill. Strut's semaglutide page, read 13 September 2026, prints $129 a month on auto-refill for injectable semaglutide and $199 for a 30-day supply of oral semaglutide, consultations and shipping included. The $99 and $149 came from the descriptions Google showed for Strut's pages and appear nowhere on the page.
- We were wrong2026-09-13
Was: $368 a month: a $19 membership plus Novo's $349 for Wegovy. Now: $498 a month after the first: LifeMD's $149 weight-loss program fee plus Novo's $349 for Wegovy. The $19 is LifeMD+, LifeMD's general membership, not its weight-loss program. LifeMD's weight-management page, read 13 September 2026, charges $39 for the first month of the program and $149 a month after, and says medication cost is not included.
- We were wrong2026-09-13
Wegovy's weight at the start of the withdrawal trial, and the loss before randomization
Was: 106.8 kg at the start, the mean of all 902 enrolled, against 96.1 kg at randomization for the 803 randomized: a run-in loss of 10.7 kg, or 10% of body weight. Now: 107.2 kg at the start and 96.1 kg at randomization, both for the 803 randomized: a run-in loss of 11.1 kg, or 10.4% of body weight. The page set the mean starting weight of all 902 people enrolled, 106.8 kg, against the mean weight at randomization of the 803 who went on, 96.1 kg. Table 9 of the label gives 107.2 kg at the start for those same 803, so the run-in loss is 11.1 kg, or 10.4% of body weight.
- We were wrong2026-09-13
Which Ozempic dose the label sets for kidney and heart risk
Was: Also the dose used for kidney and cardiovascular risk reduction. Now: Also the maintenance dose for people with type 2 diabetes and chronic kidney disease, reached after at least 4 weeks at 0.5 mg. The schedule said 1 mg is the dose used for kidney and cardiovascular risk reduction. Section 2.2 of the label sets 1 mg as the maintenance dose only for people with type 2 diabetes and chronic kidney disease; the cardiovascular indication has no dose of its own.
- We were wrong2026-09-13
Removed: Saxenda is tolerated less well than the weekly drugs
Was: A daily injection means the gastrointestinal effects arrive daily rather than weekly, which is one reason it is tolerated less well than the weekly drugs. Nausea, diarrhea, vomiting and constipation are the reason most people stop. They are worst in the first days after each dose increase and usually settle; a schedule held longer at one step is the standard answer, and it is a conversation with the prescriber rather than a reason to quit unannounced. Now: In the adult trials 9.8% of people on Saxenda stopped because of side effects, against 4.3% on placebo, most often for nausea (2.9%), vomiting (1.7%) or diarrhea (1.4%). If a dose increase is not tolerated, the label says to consider waiting about one more week before the next one, which is a conversation with the prescriber rather than a reason to quit unannounced. The note said a daily injection is one reason Saxenda is tolerated less well than the weekly drugs. The Saxenda label, the page's only source, compares it with no weekly drug. What section 6.1 does report is now in its place: 9.8% of adults stopped because of side effects, against 4.3% on placebo.
- We were wrong2026-09-13
What Foundayo's label says to do when side effects do not settle
Was: A tablet rather than an injection, and the same class effects: the route changes, the stomach does not. Nausea, diarrhea, vomiting and constipation are the reason most people stop. They are worst in the first days after each dose increase and usually settle; a schedule held longer at one step is the standard answer, and it is a conversation with the prescriber rather than a reason to quit unannounced. Now: A tablet rather than an injection, and the same class effects: the route changes, the stomach does not. In the two trials 8% stopped because of side effects, against 3% on placebo, 5% of them because of gastrointestinal ones. Nausea, vomiting and diarrhea were more common during dose escalation and decreased over time. Above 5.5 mg every step is optional, taken on response and tolerability, so the pace is a conversation with the prescriber rather than a reason to quit unannounced. The note said holding longer at one step is the standard answer, and that side effects are worst in the first days after each increase. Foundayo's label says neither: section 2.1 makes every step above 5.5 mg optional, on response and tolerability, and section 6.1 says nausea, vomiting and diarrhea were more common during escalation and decreased over time.
- We were wrong2026-09-13
What Ozempic's label says about stopping over stomach side effects
Was: This is the diabetes label. Prescribed for weight loss it is off-label, which changes nothing about the side effects and everything about whether a plan will pay. Nausea, diarrhea, vomiting and constipation are the reason most people stop. They are worst in the first days after each dose increase and usually settle; a schedule held longer at one step is the standard answer, and it is a conversation with the prescriber rather than a reason to quit unannounced. Now: This is the diabetes label. Prescribed for weight loss it is off-label, which changes nothing about the side effects and everything about whether a plan will pay. Gastrointestinal reactions made 3.1% of patients stop at 0.5 mg and 3.8% at 1 mg, against 0.4% on placebo, and most nausea, vomiting and diarrhea came during dose escalation. Side effects that do not settle are a conversation with the prescriber rather than a reason to quit unannounced. The note said stomach side effects are the reason most people stop and that holding a dose longer is the standard answer. Ozempic's label gives only the share who stopped because of them, 3.1% at 0.5 mg and 3.8% at 1 mg against 0.4% on placebo, and carries no instruction to hold a dose longer.
- We were wrong2026-09-13
Mounjaro's schedule beside Zepbound's, and what its label says about stopping over side effects
Was: Same molecule as Zepbound at the same doses, on the diabetes label. Nausea, diarrhea, vomiting and constipation are the reason most people stop. They are worst in the first days after each dose increase and usually settle; a schedule held longer at one step is the standard answer, and it is a conversation with the prescriber rather than a reason to quit unannounced. Now: Same molecule and the same pen strengths as Zepbound, on the diabetes label, but a different schedule. Mounjaro goes up from 2.5 mg only if glucose control needs it, in 2.5 mg steps at least 4 weeks apart, and stops at 10 mg for children 10 and older. Gastrointestinal reactions made 3.0% of adults stop at 5 mg, 5.4% at 10 mg and 6.6% at 15 mg, against 0.4% on placebo, and most nausea, vomiting and diarrhea comes during dose escalation and eases over time. Side effects that do not settle are a conversation with the prescriber rather than a reason to quit unannounced. The note said Mounjaro is Zepbound at the same doses. Since the August 2026 label the schedules differ: Mounjaro rises from 2.5 mg only if glucose control needs it and stops at 10 mg for children, while Zepbound's 2.5 mg is not a maintenance dose. The note also called stomach side effects the reason most people stop and prescribed a longer hold at one step; Mounjaro's label gives only the rates at which they made people stop, and no such instruction.
- We were wrong2026-09-13
What Zepbound's label says to do when side effects do not settle
Was: Nausea, diarrhea, vomiting and constipation are the reason most people stop. They are worst in the first days after each dose increase and usually settle; a schedule held longer at one step is the standard answer, and it is a conversation with the prescriber rather than a reason to quit unannounced. Now: Most people who stop Zepbound because of side effects do so in the first few months, over gastrointestinal reactions such as nausea, vomiting and diarrhea. In the two weight trials 4.8% to 6.7% stopped because of side effects, rising with the dose, against 3.4% on placebo. Most nausea, vomiting and diarrhea comes during dose escalation and eases over time. If a maintenance dose is not tolerated, the label's answer is a lower maintenance dose, which is a conversation with the prescriber rather than a reason to quit unannounced. The note said holding a dose longer at one step is the standard answer to stomach side effects, and that they are worst in the first days after each increase. Zepbound's label says neither: section 2.1 says to consider a lower maintenance dose if one is not tolerated, and section 6.1 says most nausea, vomiting and diarrhea came during dose escalation and decreased over time.
- We were wrong2026-09-13
How many Wegovy run-in dropouts stopped because of side effects
Was: Ninety-nine of the 902 enrolled stopped during the 20-week run-in, most of them because of adverse reactions. Now: Ninety-nine of the 902 enrolled stopped during the 20-week run-in; adverse reactions were the most common reason, for 48 of them. The page said most of the 99 people who stopped during the run-in did so because of adverse reactions. Section 14.2 of the label gives 48 of the 99: the most common reason, but not a majority.
- We were wrong2026-09-13
Whether Contrave's side effects are gastrointestinal, and when opioids rule it out
Was: This is not a GLP-1: it is naltrexone plus bupropion, and its risks are neurological and cardiovascular rather than gastrointestinal. Anyone taking an opioid, including buprenorphine for addiction, cannot take it at all. Now: This is not a GLP-1: it is naltrexone plus bupropion, and its boxed warning and main serious risks concern mood, seizures, opioid use and blood pressure. Its most common side effect is still nausea: in the trials 24% stopped because of an adverse event, against 12% on placebo, and nausea was the most common reason, at 6.3%. Anyone on long-term opioid treatment, including buprenorphine for addiction, cannot take it; for a short course of opioids it is paused, and lower opioid doses may be needed. The note said Contrave's risks are neurological and cardiovascular rather than gastrointestinal, and that anyone taking an opioid cannot take it at all. Section 6.1 of the label makes nausea the most common side effect and the most common reason people stop, at 6.3%. The contraindication covers chronic opioid use; for intermittent opioid treatment, section 5.4 says to pause Contrave.
- We were wrong2026-09-13
Removed: how liraglutide compared with weekly semaglutide and dulaglutide in trials
Was: Seven injections a week. Head to head, weekly semaglutide 1 mg lowered HbA1c and weight more than daily liraglutide 1.2 mg in SUSTAIN 10, but weekly dulaglutide 1.5 mg only matched liraglutide 1.8 mg on HbA1c in AWARD-6. It is here because it is still prescribed and still asked about. Now: Seven injections a week. It is here because it is still prescribed and still asked about. The note reported two head-to-head trials, SUSTAIN 10 and AWARD-6, under a citation to the Victoza label alone. The label mentions neither trial nor either comparison drug; the results come from journal papers, so they have been taken off a schedule whose one source is the label.
- We were wrong2026-09-13
The label section cited for the Zepbound stopping trial
Was: FDA prescribing information for ZEPBOUND, section 14.4. Now: FDA prescribing information for ZEPBOUND, section 14.1. The citation named section 14.4. The current Zepbound label, published 2 September 2026, has no such section: its clinical studies run to 14.2, and Study 4, the withdrawal trial, is under 14.1. Every figure on the page matches 14.1; only the section number was wrong.
- We were wrong2026-09-13
When kidney or liver impairment limits the Qsymia dose
Was: Kidney or liver impairment of any degree caps the dose at 7.5 mg/46 mg. Now: Moderate or severe kidney impairment, or moderate liver impairment, caps the dose at 7.5 mg/46 mg; mild impairment changes nothing; on dialysis or with severe liver impairment, Qsymia is not to be used. The schedule said kidney or liver impairment caps the dose at 7.5 mg/46 mg. Sections 2.4 and 2.5 of the label set that cap only for moderate or severe kidney impairment and moderate liver impairment. Mild impairment changes nothing, and for someone on dialysis or with severe liver impairment the label says not to use Qsymia at all, where the old line let 7.5 mg/46 mg read as allowed.
- We were wrong2026-09-13
Who may stay on 2.4 mg of Saxenda
Was: The recommended dose. Escalation in children can take up to 8 weeks, and 2.4 mg is allowed if 3 mg is not tolerated. Now: The recommended dose. For adults the lower doses are for titration only: an adult who cannot tolerate 3 mg stops Saxenda. Children 12 and older who cannot tolerate 3 mg may drop to 2.4 mg, and stop if that is not tolerated either; their escalation can take up to 8 weeks. The schedule said 2.4 mg is allowed if 3 mg is not tolerated, which read as applying to everyone. Section 2.2 of the label allows it only for children 12 and older. For adults the lower doses are for titration only, and an adult who cannot tolerate 3 mg stops the drug.
- We were wrong2026-09-12
Who qualifies for the Medicare GLP-1 Bridge
Was: …and who meet one of the demonstration's BMI and clinical categories. Now: …BMI 35+, or 30+ with one of three conditions, or 27+ with prediabetes, a previous heart attack or stroke, or symptomatic peripheral artery disease. Read from medicare.gov/glp1bridge (which redirects to medicare.gov/coverage/weight-loss-drugs) on 12 September 2026. The line told a reader to find the criteria elsewhere; CMS publishes them: BMI 35+, BMI 30+ with diastolic heart failure, uncontrolled hypertension or stage 3a kidney disease, or BMI 27+ with prediabetes, a previous heart attack or stroke, or symptomatic peripheral artery disease.
- We were wrong2026-09-12
Why the label allows 1.7 mg of Wegovy
Was: The recommended maintenance dose; 1.7 mg is the alternative if 2.4 is not tolerated. Now: 1.7 mg is a maintenance dose in its own right on the label, chosen on response as well as tolerability. The step note said 1.7 mg is what you take if 2.4 mg is not tolerated. Section 2.2 lists 1.7 mg and 2.4 mg as the adult maintenance dosages, 2.4 mg recommended, and tells the prescriber to consider treatment response as well as tolerability when choosing between them.
- We were wrong2026-09-12
The condition listed for Contrave Home Delivery
Was: Contrave's label trial measured 5.4% weight loss against 20.9% in tirzepatide's own trial — separate trials, but a gap wide enough that the low price buys a materially weaker result. It was halfrx's own cross-trial comparison, which Currax does not publish; the program lists no condition beyond a prescription.
- We were wrong2026-09-12
What $499 and $647 mean on the Mounjaro savings card
Was: Capped at $150 of savings a month and $1,950 a year. Without coverage the same card gives $499 a month, capped at $647 monthly and $8,411 a year. Now: Capped at $150 of savings a month and $1,950 a year. Without coverage the same card lets you pay as little as $499 for a 28-day fill, with Lilly's savings in that case capped at $647 a month and $8,411 a year. Without coverage, $499 is what the patient pays for a fill and $647 a month caps Lilly's savings; the old wording read as if the card paid $499 and capped it at $647.
- We were wrong2026-09-12
What the Zepbound savings card does without coverage
Was: Requires a commercial plan that already covers the Zepbound single-dose pen. Lilly's terms exclude anyone in a state, federal or government-funded program, and the list is longer than Medicare and Medicaid: Medicare Part D, Medicare Advantage, Medigap, DoD, VA and TRICARE are all named in it. Now: The $25 needs a commercial plan that already covers the Zepbound single-dose pen. Without coverage the same card lets you pay as little as $499 for a 28-day fill of the single-dose pen, up to 13 fills a year, or for the KwikPen as little as $299 at 2.5 mg, $399 at 5 mg and $449 from 7.5 mg up. Lilly's terms exclude anyone in a state, federal or government-funded program, and the list is longer than Medicare and Medicaid: Medicare Part D, Medicare Advantage, Medigap, DoD, VA and TRICARE are all named in it. The pages said that without coverage there was no copay for the card to reduce. Lilly's own terms give a separate rate for that case: as little as $499 for the single-dose pen and $299 to $449 for the KwikPen.
- Price2026-09-11
Costco / Success by Sesame re-checked
Scored on a starting price, as month-to-month and cash only
- Price2026-09-11
Rybelsus showed another tablet's price
- Price2026-09-11
Henry Meds' low price belonged to another drug
- Price2026-09-11
Hone Health's maintenance price
- Price2026-09-11
Noom's lowest tier went up
- Price2026-09-11
Compounded tirzepatide re-checked
From Noom Med and Found
- Price2026-09-10
tracker figure cleared; the seller's site refuses every read
- Price2026-09-10
NovoCare prints $149/$199/$299 by dose; the card's ladder is unchanged
- Price2026-09-10
figure withdrawn: CVS publishes no monthly price
- Price2026-09-10
cash price read from Found's own pricing pages
- Price2026-09-10
price cut by the seller; only floors published
- Price2026-09-09
was $199 flat
- Price2026-09-07
was unpriced
- Price2026-09-07
was unpriced
- Price2026-09-05
figure withdrawn: the seller no longer publishes one, read 2026-09-05
- Price2026-09-05
figure withdrawn: the seller no longer publishes one, read 2026-09-05
- Price2026-09-05
$499 a month self-pay at every strength on lilly.com/lillydirect/mounjaro; unchanged
- Price2026-09-05
Costco / Success by Sesame now $208 a month
Sesame's own page, $59 care plus $149 medication, read 2026-09-05
- Price2026-09-05
Henry's own program list, read 2026-09-05
- Price2026-09-04
Compounded semaglutide re-checked
From Strut Health, Zealthy, Lemonaid Health and Noom Med
August 2026
- Price2026-08-30
figure withdrawn: Found published medication prices only, with no membership fee
- Price2026-08-20
Compounded semaglutide re-checked
From Strut Health, Zealthy, Found, Lemonaid Health, Noom Med and Henry Meds
- Price2026-08-20
Compounded semaglutide re-checked
From Strut Health, Zealthy, Found, Lemonaid Health, Noom Med and Henry Meds
- Price2026-08-20
Compounded tirzepatide re-checked
From Noom Med and Found
- Price2026-08-20
Compounded tirzepatide re-checked
From Noom Med and Found
- Price2026-08-19
Compounded tirzepatide re-checked
From Noom Med and Mochi Health
- Price2026-08-19
Compounded semaglutide re-checked
From Strut Health, Zealthy, Mochi Health, Lemonaid Health, Noom Med and Henry Meds
- Price2026-08-19
From Hone Health
- Price2026-08-19
Compounded semaglutide re-checked
From Strut Health, Zealthy, Mochi Health, Lemonaid Health, Noom Med and Henry Meds
July 2026
- On a seller's record2026-07-29
Hims & Hers: FTC, California and Utah v. Hims & Hers Health, Inc.
- State coverage2026-07-03
Massachusetts changed what its Medicaid program covers
Coverage of every anti-obesity agent — Wegovy, Zepbound, Saxenda, phentermine, orlistat — ended for weight loss; GLP-1s stay only for cardiovascular risk, sleep apnea, MASH or diabetes
- State coverage2026-07-01
Utah changed what its Medicaid program covers
The weight-loss pilot lapsed: Utah's own prior-authorization form caps every obesity authorization at 30 June 2026 and no longer has an initial-approval route for obesity
June 2026
- State coverage2026-06-09
Louisiana changed what its Medicaid program covers
Act 898 signed: weight-loss drugs to be covered, no step therapy — in force only once money is appropriated for it
- On a seller's record2026-06-04
Mochi Health: Are GLP-1 compounds safe? Not from this SF company and WA supplier, whistleblowers say
March 2026
- Offer ends2026-03-31
Ozempic and Wegovy cash price via GoodRx ends
GoodRx with Novo Nordisk publishes it at $199 a month for the first two fills at 0.25 mg and 0.5 mg, then $349, with this as the last day.
January 2026
- State coverage2026-01-01
New Hampshire changed what its Medicaid program covers
GLP-1s for obesity eliminated; other weight-loss drugs stay
- State coverage2026-01-01
Michigan changed what its Medicaid program covers
Coverage kept, but narrowed to morbid obesity with documented failure of every other intervention and only to avert bariatric surgery
- State coverage2026-01-01
California changed what its Medicaid program covers
GLP-1s for weight loss dropped entirely; every existing approval expired on 31 December 2025 with no continuing care
- State coverage2026-01-01
Pennsylvania changed what its Medicaid program covers
GLP-1s for obesity eliminated; other weight-loss drugs stay
- State coverage2026-01-01
South Carolina changed what its Medicaid program covers
GLP-1s for obesity eliminated
December 2025
- State coverage2025-12-12
North Carolina changed what its Medicaid program covers
Coverage reinstated, reverting to the criteria in force on 30 September 2025
October 2025
- State coverage2025-10-01
North Carolina changed what its Medicaid program covers
GLP-1s for obesity dropped during the state budget stalemate
July 2025
- State coverage2025-07-31
Connecticut changed what its Medicaid program covers
GLP-1s for members without type 2 diabetes stop paying; orlistat and phentermine covered from 1 July
June 2025
- On a seller's record2025-06-23
Hims & Hers: Novo Nordisk terminates collaboration with Hims & Hers Health, Inc.
April 2025
- On a seller's record2025-04-23
Mochi Health: Eli Lilly sues four telehealth sites selling compounded Zepbound, Mounjaro
- On a seller's record2025-04-23
Henry Meds: Eli Lilly sues four telehealth sites selling compounded Zepbound, Mounjaro
How this log works
- Why does a price need a date?
- Because the alternative is what happened to Lilly's Zepbound savings card. Its annual cap fell from $1,950 to $1,300, and a year later the old figure was still in circulation — quoted by a site ranking fourth for the query, in its own FAQ, on a page that also quoted the new one in a different block. Neither carried a date. A figure with no read date cannot be checked, and cannot be noticed going stale.
- What counts as a change here?
- A verified price moving, a state changing what its Medicaid program covers, a published offer reaching its end date, a documented event on a seller's public record, and this site being wrong about something. Not: a page being edited, a design change, or a first recording of a figure that had never been recorded before — those are not news and are left out rather than used to fill the month.
- How often is this updated?
- The price checker runs nightly and proposes changes; a person approves each one before it reaches a page, and the approval lands here beside the re-checks and corrections made by hand. State coverage and press events are added when the document appears. If a month below is thin, that is the month rather than a gap in the record.
Every entry carries the date the change happened, and a link to the document behind it wherever there is one. Where a stream has nothing to report, this page says so rather than filling the month.